Anti-aging biotech upstart plucks a drug from Amgen’s discard pile, pivoting from heart failure to muscle conditions

Back in April 2019, Amgen quietly shut down a Phase I trial for a drug named AMG 986. There was no safety concern; the molecule just didn’t hit the mark on helping the small band of heart failure patients who received it.

A small biotech, though, believes it would stand…